KD PHARMA STRENGTHENS ITS TECHNOLOGY PLATFORM BY ACQUIRING UK MANUFACTURING SITE
Acquisition allows KD Pharma to further expand its leading position in the omega-3 pharmaceutical market
BIOGGIO, SWITZERLAND – May 30, 2019 – KD Pharma Group SA announced that it has acquired a manufacturing site in Seal Sands, United Kingdom. The KD Pharma UK LTD entity will expand KD Pharma’s capacity for manufacturing omega-3-based intermediates used in producing active pharmaceutical ingredients (APIs). The site was previously used for manufacturing omega-3 products.
“This acquisition expands our technology and manufacturing base for producing APIs with the highest concentrations of EPA and DHA omega-3s,” said Oscar Groet, KD Pharma Group’s Chief Executive Officer. “The breadth of our technology platform sets KD Pharma apart, no company has more technologies for isolating and fractionating lipids,” he concluded.
KD Pharma Group strives to be the leading manufacturer in the rapidly growing omega-3 API market. The UK acquisition will enable it to meet market demand for the highest quality APIs in response to new product approvals, label expansions, and supportive clinical research. The company says the site will be brought online this year and operated alongside KD Pharma Group’s other manufacturing sites in Bexbach, Germany; Brattvag, Norway; and Miami, United States.
About the KD Pharma Group SA
The KD Pharma Group is the third largest Omega-3 producer in the world with 400 people and 7 sites located in the UK, Norway, Germany and the US. The company concentrates nutraceutical and pharmaceutical oils and makes customized finished products for its customers in soft gel capsule and bottled liquid forms. The KD Pharma Group has the global reach, technology and vertical integration necessary to develop customized Omega-3 products with complete supply chain efficiency for our customers. Visit KDPharmaGroup.com to learn more.
Chief Strategy Officer
KD Pharma Group
+1 (385) 237-2787